Abstract:Purpose of review: Opioid receptors are widely expressed in the human brain. A number of features commonly associated with drug use disorder, such as difficulties in emotional learning, emotion regulation and anhedonia, have been linked to endogenous opioid signalling. Whereas chronic substance use and misuse are thought to alter the function of the mu-opioid system, the specific mechanisms are not well understood. We argue that understanding exogenous and endogenous opioid effects in the healthy human brain is an essential foundation for bridging preclinical and clinical findings related to opioid misuse. Here, we will examine psychopharmacological evidence to outline the role of the mu-opioid receptor (MOR) system in the processing of threat and reward, and discuss how disruption of these processes by chronic opioid use might alter emotional learning and reward responsiveness. Recent findings: In healthy people, studies using opioid antagonist drugs indicate that the brain's endogenous opioids downregulate fear reactivity and upregulate learning from safety. At the same time, endogenous opioids increase the liking of and motivation to engage with high reward value cues. Studies of acute opioid agonist effects indicate that with non-sedative doses, drugs such as morphine and buprenorphine can mimic endogenous opioid effects on liking and wanting. Disruption of endogenous opioid signalling due to prolonged opioid exposure is associated with some degree of anhedonia to non-drug rewards; however, new results leave open the possibility that this is not directly opioid-mediated. Summary: The available human psychopharmacological evidence indicates that the healthy mu-opioid system contributes to the regulation of reward and threat processing. Overall, endogenous opioids can subtly increase liking and wanting responses to a wide variety of rewards, from sweet tastes to feelings of being connected to close others. For threat-related processing, human evidence suggests that endogenous opioids inhibit fear conditioning and reduce the sensitivity to aversive stimuli, although inconsistencies remain. The size of effects reported in healthy humans are however modest, clearly indicating that MORs play out their role in close concert with other neurotransmitter systems. Relevant candidate systems for future research include dopamine, serotonin and endocannabinoid signalling. Nevertheless, it is possible that endogenous opioid fine-tuning of reward and threat processing, when unbalanced by e.g. opioid misuse, could over time develop into symptoms associated with opioid use disorder, such as anhedonia and depression/anxiety.

Differential effects of acute and prolonged morphine withdrawal on motivational and goal‐directed control over reward‐seeking behaviour

Morphine Epigenomically Regulates Behavior Through Alterations in Histone H3 Lysine 9 Dimethylation in the Nucleus Accumbens

Mesoaccumbens Dopamine Signaling Alteration Underlies Behavioral Transition from Tolerance to Sensitization to Morphine Rewarding Properties During Morphine Withdrawal

VTA μ-opioidergic neurons facilitate low sociability in protracted opioid withdrawal

Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice

Striatal μ-opioid receptor activation triggers direct-pathway GABAergic plasticity and induces negative affect

Sex-specific behavioral and thalamo-accumbal circuit adaptations after oxycodone abstinence

Region-specific Alterations in Glutamate Receptor 1 Phosphorylation During Context-Induced Drug Seeking after Withdrawal from Morphine Self-Administration

Alterations in phosphorylated CREB expression in different brain regions following short- and long-term morphine exposure: relationship to food intake

Region-specific alterations in glutamate receptor 1 phosphorylation during context-induced drug seeking after withdrawal from morphine self-administration.

Morphine Withdrawal Affects Both Delayed-Escape Behaviour in Morris Water Maze and Hippocampal NR2A/2B Expression Ratio.

Validation of drug‐nondrug choice procedure to model maladaptive behavioural allocation to opioid use in rats

Modulation of the mTOR pathway in male Lewis rats after morphine self-administration and subsequent extinction training

Long-lasting effects of adolescent oxycodone exposure on reward-related behavior and gene expression in mice

Naloxone-precipitated withdrawal enhances ERK phosphorylation in prefrontal association cortex and accumbens nucleus of morphine-dependent mice.

Morphine Differentially Alters the Synaptic and Intrinsic Properties of D1R- and D2R-Expressing Medium Spiny Neurons in the Nucleus Accumbens

Characterization and validation of a spontaneous acute and protracted oxycodone withdrawal model in male and female mice

Expression Changes of Hippocampal Energy Metabolism Enzymes Contribute to Behavioural Abnormalities During Chronic Morphine Treatment

The Role of Mu-Opioids for Reward and Threat Processing in Humans: Bridging the Gap from Preclinical to Clinical Opioid Drug Studies

Decreased Neuronal Excitability in Medial Prefrontal Cortex during Morphine Withdrawal is associated with enhanced SK channel activity and upregulation of small GTPase Rac1

Opioid withdrawal: role in addiction and neural mechanisms